

Connecting genomic and proteomic signatures of amyloid burden in the brain

Raquel Puerta^{1,2†}, Itziar de Rojas^{1,3†}, Pablo García-González^{1,3}, Clàudia Olivé¹, Oscar Sotolongo-Grau¹, Ainhoa García-Sánchez¹, Fernando García-Gutiérrez¹, Laura Montreal¹, Juan Pablo Tartari¹, Ángela Sanabria^{1,3}, Vanesa Pytel^{1,3}, Carmen Lage^{4,3}, Inés Quintela⁵, Nuria Aguilera¹, Eloy Rodriguez-Rodriguez^{4,3}, Emilio Alarcón-Martín¹, Adelina Orellana^{1,3}, Pau Pastor^{6,7}, Jordi Pérez-Tur^{8,3,9}, Gerard Piñol-Ripoll^{10,11}, Adolfo López de Munian^{12,13,3,14}, Jose María García-Alberca^{15,3}, Jose Luís Royo¹⁶, María Jesús Bullido^{17,3,18,19}, Victoria Álvarez^{20,21}, Luis Miguel Real^{22,16}, Arturo Corbatón Anchuelo²³, Dulcenombre Gómez-Garre^{23,24,25}, María Teresa Martínez Larrad^{23,26}, Emilio Franco-Macías²⁷, Pablo Mir^{28,3}, Miguel Medina^{29,3}, Raquel Sánchez-Valle³⁰, Oriol Dols-Icardo³¹, María Eugenia Sáez³², Ángel Carracedo^{5,33}, Lluís Tàrraga^{1,3}, Montse Alegret^{1,3}, Sergi Valero^{1,3}, Marta Marquié^{1,3}, Mercè Boada^{1,3}, Pascual Sánchez Juan^{4,3}, Jose Enrique Cavazos³⁴, Alfredo Cabrera³⁵, Amanda Cano^{1,3‡}, Agustín Ruiz^{1,3,‡,*} for the Alzheimer's Disease Neuroimaging Initiative.

¹Ace Alzheimer Center Barcelona – Universitat Internacional de Catalunya, Spain.

²Universitat de Barcelona (UB). ³CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.

⁴Neurology Service, Marqués de Valdecilla University Hospital (University of Cantabria and IDIVAL), Santander, Spain. ⁵Grupo de Medicina Xenómica, Centro Nacional de Genotipado (CEGEN-PRB3-ISCIII). Universidade de Santiago de Compostela, Santiago de Compostela, Spain.

⁶Unit of Neurodegenerative diseases, Department of Neurology, University Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain. ⁷The Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.

⁸Unitat de Genètica Molecular, Institut de Biomedicina de València-CSIC, Valencia, Spain. ⁹Unidad Mixta de Neurología Genética, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.

¹⁰Unitat Trastorns Cognitius, Hospital Universitari Santa Maria de Lleida, Lleida, Spain.


¹¹Institut de Recerca Biomedica de Lleida (IRBLLeida), Lleida, Spain. ¹²Department of Neurology. Hospital Universitario Donostia. San Sebastian, Spain. ¹³Department of Neurosciences. Faculty of Medicine and Nursery. University of the Basque Country, San Sebastián, Spain.

¹⁴Neurosciences Area. Instituto Bionostia. San Sebastian, Spain.


¹⁵Alzheimer Research Center & Memory Clinic, Andalusian Institute for Neuroscience,

Málaga, Spain. ¹⁶Departamento de Especialidades Quirúrgicas, Bioquímica e Inmunología. School of Medicine. University of Malaga. Málaga, Spain. ¹⁷Centro de Biología Molecular Severo Ochoa (UAM-CSIC). ¹⁸Instituto de Investigación Sanitaria ‘Hospital la Paz’ (IdIPaz), Madrid, Spain. ¹⁹Universidad Autónoma de Madrid. ²⁰Laboratorio de Genética. Hospital Universitario Central de Asturias, Oviedo, Spain. ²¹Instituto de Investigación Sanitaria del Principado de Asturias (ISPA). ²²Unidad Clínica de Enfermedades Infecciosas y Microbiología. Hospital Universitario de Valme, Sevilla, Spain. ²³Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Hospital Clínico San Carlos. ²⁴Laboratorio de Riesgo Cardiovascular y Microbiota, Hospital Clínico San Carlos; Departamento de Fisiología, Facultad de Medicina, Universidad Complutense de Madrid (UCM). ²⁵Biomedical Research Networking Center in Cardiovascular Diseases (CIBERCV), Madrid, Spain. ²⁶Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM). ²⁷Dementia Unit, Department of Neurology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBiS), Sevilla, Spain. ²⁸Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología. Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain. ²⁹CIEN Foundation/Queen Sofia Foundation Alzheimer Center. ³⁰Alzheimer's disease and other cognitive disorders unit. Service of Neurology. Hospital Clínic of Barcelona. Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain. ³¹Department of Neurology, Sant Pau Memory Unit, Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. ³²CAEBI, Centro Andaluz de Estudios Bioinformáticos, Sevilla, Spain. ³³Fundación Pública Galega de Medicina Xenómica – CIBERER-IDIS, Santiago de Compostela, Spain. ³⁴South Texas Medical Science Training Program, University of Texas Health San Antonio, San Antonio. ³⁵Neuroscience Therapeutic Area, Janssen Research & Development, Turnhoutseweg 30, 2340 Beerse, Belgium.


Supplementary Figures




Supplementary Figure 1. Workflow of this study for each cohort and endophenotypes. ACE cohort used both Innostest ELISA kits (1) and CLEIA Lumipulse (2) for measuring CSF A β 42 endophenotypes.




Supplementary Figure 2. Histograms of the CSF and PET endophenotypes distribution after the data harmonization.



Supplementary Figure 3. Manhattan plot of the gene-based analysis of MAGMA (FUMA). Genes highlighted in blue were previously related to AD and its endophenotypes. Red line: significance threshold at $P < 4.235e-06$.



Supplementary Figure 4. Top10 enriched mechanisms of the ORA analysis using the WebGestalt tool. A) Considering proteins significantly associated with CSF $A\beta_{42}$ levels ($n=1,387$), and B) considering the complete set of proteins ($n=2,648$) included in CSF proteome analyses.



Supplementary Figure 5. Venn diagram of the overlapping loci/proteins in genomic and proteomic analysis considering the PAD (light blue) and our CSF-PET meta-analysis (yellow).

Supplementary Material

1. AD risk and reported amyloidosis genes in the literature

We analysed the effect of AD genes described in Bellenguez *et al* in our A β endophenotype study. A total of 12 genes were not considered for replication due to low frequency or missingness in the imputation process. Although the extensive filter of genetic markers did not allow us to evaluate all markers, rs679515-*CRI* was significantly replicated in our amyloid burden meta-analysis ($P < 0.05$). Interestingly, this variant was not significant independently in CSF or PET meta-GWAS, but the combination of A β endophenotypes allowed us to gain power and replicate it. Additionally, the genetic marker located in the rs6943429-*UMADI* gene had a consistent effect in the combined A β burden meta-analysis but did not reach significance. Moreover, the rs113706587-*RASGEF1C* loci were only significantly replicated in the PET meta-analysis. In contrast, both rs6014724-*CASS4* and rs6605556-*HLA-DQA1* markers were significantly replicated in the CSF A β 42 meta-analysis and also had a consistent effect size direction in the PET centiloid meta-analysis. Thirty-five and thirty-four additional genetic markers had a consistent effect with what was observed in Bellenguez *et al* study in CSF A β 42 and PET centiloid meta-analysis, respectively (Supplementary Table 2).

Regarding the genetic variants reported in Jansen *et al* for amyloidosis, the rs429358-*APOE* variant was significantly replicated in all A β meta-analyses while the rs4844610-*CRI* variant had a consistent effect in all meta-analyses: it was nominally replicated in CSF A β 42 and significantly replicated in the final A β burden combined meta-analysis ($P < 0.05$; Supplementary Table 3). Finally, we also aimed to replicate markers associated to neuropathological features described in Beecham *et al*. The rs6857 and rs429358 were significantly replicated in all meta-analysis as well as the meta-analysis of CSF-PET endophenotypes. These variants were both located in the *APOE* region and associated with NFTs, neuritic plaques and other phenotypes (Supplementary Table 4).